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Background: Accumulating evidence suggests a tumor suppressive role for miR-34a in human carcinogenesis.
However, its precise biological role remains largely elusive. This study aimed to reveal the association of the
miR-34a expression and its modulation of sensitivity to cisplatin in muscle-invasive bladder cancer (MIBC).
Methods: miR-34a expression in MIBC cell lines and patient tissues was investigated using qPCR. The methylation
analysis of miR-34a promoter region was performed by MassARRAY. Synthetic short single or double stranded RNA
oligonucleotides and lentiviral vector were used to regulate miR-34a expression in MIBC cells to investigate its
function in vitro and in vivo.
Results: miR-34a expression was frequently decreased in MIBC tissues and cell lines through promoter
hypermethylation while it was epigenetically increased in MIBC cells following cisplatin treatment. Increased
miR-34a expression significantly sensitized MIBC cells to cisplatin and inhibited the tumorigenicity and proliferation
of cancer cells in vitro and in vivo. Furthermore, we identified CD44 as being targeted by miR-34a in MIBC cells
following cisplatin treatment, and increased CD44 expression could efficiently reverse the effect of miR-34a on MIBC
cell proliferation, colongenic potential and chemosensitivity.
Conclusions: Cisplatin-based chemotherapy induced demethylation of miR-34a promoter and increased miR-34a
expression, which in turn sensitized MIBC cells to cisplatin and decreased the tumorigenicity and proliferation of
cancer cells that by reducing the production of CD44.
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Bladder cancer is the ninth most common cancer diag-
nosis worldwide, with more than 330,000 new cases each
year and more than 130,000 deaths per year [1]. At any
point in time, 2.7 million people have a history of urin-
ary bladder cancer [1]. At the initial diagnosis of bladder
cancer, 70% of cases are diagnosed as non-muscle-
invasive bladder cancer (NMIBC) and approximately 30%
as muscle-invasive bladder cancer (MIBC). The standard
treatment for patients with muscle-invasive bladder cancer
is radical cystectomy. However, as approximately one-* Correspondence: xiaowei0041@163.com; xuhua@mail.hust.edu.cn
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reproduction in any medium, provided the orthird of patients diagnosed with MIBC have undetected
metastases at the time of treatment for the primary tumor
and 25% of patients who undergo radical cystectomy
present with lymph node involvement at the time of sur-
gery, this ‘gold standard’ only provides 5-year survival in
about 50% of patients [2]. In order to improve these unsat-
isfactory results, peri-operative chemotherapy has been
explored since the 1980s. The updated analysis shows that
cisplatin-based neoadjuvant chemotherapy significantly
improves overall survival. However, as only about 50% of
patients with MIBC will respond to cisplatin-based
chemotherapy [3], there is still an urgent need to further
investigate the mechanisms that prevent response to
chemotherapy.
MiRNAs are endogenous, non-coding RNA molecules
of approximately 19–25 nucleotides in length. Most
miRNAs represses mRNA translation by blocking ofhis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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minor proportion of the miRNAs mediate mRNA target
up-regulation [4]. Depending on their target genes, miR-
NAs have been shown to be associated with many types
of cancers and involved in every aspect of cancer includ-
ing proliferation, differation, metastasis and chemosensi-
tivity [5]. Among these miRNAs, miR-34a has been
described as a “star” miRNAs in cancer research, which
commonly functions as a tumor suppressor and is
down-regulated in many human cancers [6]. Further-
more, the aberrant miR-34a expression has been linked
to chemotherapy resistance in a variety of cancer [7-11].
One relevant explanation for this is its regulatory func-
tion in p53 signaling pathway. miR-34a is the most sig-
nificantly inducted miRNAs by p53 and ectopic miR-34a
expression induces apoptosis, cell-cycle arrest, senes-
cence and alters cancer cell chemosensitivity through
direct targeting multiple genes in p53 signaling pathway,
such as Sirt-1, CDK6, E2F3 and Bcl-2 [12-14]. However,
this mechanism seems not fitting well in cisplatin-based
bladder cancer chemotherapy as miR-34a chemosensitizes
bladder cancer cells to cisplatin treatment regardless of
p53-Rb pathway status [9]. So the regulatory mechanism
of miR-34a in cisplatin-based bladder cancer chemother-
apy is not clear and needs further investigation.
Results
miR-34a is frequently decreased in human MIBC tissues
and cell lines through promoter hypermethylation
To investigate the role of miR-34a in MIBC, we firstly
evaluated the expression of miR-34a in four MIBC cell
lines (5637, HT1376, J82 and T24) and a non-
tumorigenic bladder cell line SV-HUC-1 by qPCR.
Compared to SV-HUC-1 cells, all of four MIBC cell lines
had a significantly lower level of miR-34a expression
(Figure 1A, P < 0.05). The expression of miR-34a was
further analyzed by qPCR in 14 paired MIBC/adjacent
normal bladder tissue specimens. And a highly signifi-
cant (Figure 1B, P < 0.01) reduction of miR-34a in 12 of
14 MIBC tissues was observed.
To explore whether promoter hypermethylation leads
to the suppression of expression, we examined the ex-
pression of miR-34a in bladder epithelial cell lines
treated with the DNA methylation inhibitor, 5-aza-dC.
After treatment, all the five cell lines showed a reactiva-
tion of miR-34a expression (Figure 1C). To further de-
tect the promoter methylation status of the miR-34a
quantitatively, the promoter CpG islands in bladder epi-
thelial cell lines and tissue was determined by quantita-
tive sequencing. As shown in Figure 1D, MassARRAY
results showed hypermethylation was detected in all
bladder cancer cell lines, while partial methylation in
non-tumorigenic cell line SV-HUC-1, which was consist-
ent with the 5-aza-dC detection. For tissues samples, 4of 5 MIBC tissues showed hypermethylation while their
paired cancer adjacent normal tissues showed partial
methylation or unmethylation, which was consistent with
the mRNA analysis (Figure 1B). Together, these results
suggested that miR-34a was down-regulated through pro-
moter hypermethylation in MIBC.
Cisplatin can upregulate miR-34a by promoter demethyla-
tion in MIBC cell lines
It is of note that aberrant expression of microRNA has
been linked to chemosensitivity, so we next examined
the expression of miR-34a in MIBC cells after cisplatin
treatment. Result showed that chemotherapy led to in-
creased miR-34a expression in all three MIBC cell lines
in a dose- and time-dependent manner (Figure 2A
and B). Subsequent epigenetic assessment also proved
that cisplatin treatment induced miR-34a promoter de-
methylation (Figure 2C and D). Taken together, these
findings provide evidence that cisplatin induced pro-
moter demethylation could be an important reason for
increased miR-34a expression in MIBC cell lines.
Increased miR-34a expression sensitizes MIBC cells to cis-
platin in vivo and in vitro
As miR-34a expression increased dramatically following
cisplatin treatment, we subsequently assessed in the as-
sociation between miR-34a and chemosensitivity. Results
of cell viability assay clearly showed that overexpression
of miR-34a in 5637, T24 and HT1376 cells could effi-
ciently increased their sensitivity to cisplatin as com-
pared to NC group (Figure 3A and B, P < 0.05). This
observation was further confirmed in T24 cell based
xenograft model by using agomir-miRNA, a chemically
modified miRNA oligonucleotide conjugated with chol-
esterol (Figure 3C and D). Importantly, statistical ana-
lysis demonstrated that the inhibition rate of each group
satisfy the formula: (miR-34a + cisplatin) > (miR-34a
alone) + (cisplatin alone), which indicated the synergistic
effect of miR-34a to cisplatin chemotherapy.
Elevated miR-34a expression inhibits proliferation and de-
creases clonogenic potential of MIBC cells in vivo and
in vitro
In order to investigate the phenotypic consequences of
miR-34a in MIBC cells, we overexpressed this miRNA in
5637, T24 and HT-1376 cells via miRNA mimics and
Lentivectors. The proliferation and clonogenic potential
were measured by CCK-8, colony formation and sphere
formation assay respectively. And a synthetized miRNA
inhibitor was also used in CCK-8 assay to further evalu-
ate miR-34a function. Compared to NC group, overex-
pression of miR-34a significantly inhibited MIBC cell
proliferation and vice versa (Figure 4A, P < 0.05), while
as shown in Figure 4B-E, elevated miR-34a expression
Figure 1 MiR-34a was epigenetically downregulated in MIBC. miR-34a expression was evaluated by qPCR in MIBC A) cell lines and B) patient
tissues, U6 served as an internal control. Methylation analysis of miR-34a promoter region: C) profiling of the unit-specific methylation of CpG sites
in the miR-34a promoter region was presented as an epigram. White circle means missing data at a given CpG unit; D) qRT-PCR demonstrated
miR-34a expression in four MIBC cell lines after treatment with 5-aza-dC compared to mock-treated cells; Average methylation level of miR-34a
promoter region in MIBC E) cell lines and F) patient tissues. Results are presented as mean + SEM of 3 independent experiments. *p < 0.05.
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tion ability of all three MIBC cell lines. Then T24 cells,
which stably expressing miR-34a or NC, were used to con-
struct the xenograft model in nude mice. As shown in
Figure 4F, at d33 post injection, there were still significant
miR-34a expression in derived xenograft. And when com-
pared with NC group, miR-34a stably expressing tumor
xenograft had markedly smaller size and lower weight(Figure 4G-I, P < 0.05). Taken together, these results dem-
onstrated that miR-34a functions as a tumor suppressor in
MIBC cells through decreasing their clonogenic potential.
CD44 is a primary target of miR-34a in MIBC cells following
cisplatin treatment
To investigate the primary target of miR-34a that may
help to explain the association between the increased
Figure 2 Expression of miR-34a increased in MIBC cell lines via promoter demethylation following cisplatin treatment. Cisplatin induced
miR-34a expression in A) doze- and B) time-dependent manner, relative to control group ( cisplatin 0 μg/ml group or 0 h group, mean + SEM;
n = 3; *p < 0.05). Methylation analysis of miR-34a promoter region: C) profiling of the unit-specific methylation of CpG sites in the miR-34a
promoter region was presented as an epigram; D) Average methylation level of miR-34a promoter region in MIBC cell lines (mean + SEM; n = 3;
*p < 0.05).
Figure 3 Overexpression of miR-34a in MIBC cells sensitized tumor cells to cisplatin chemotherapy. A) Tumor cell viability was detected
by CCK-8 assay after different treatment. Data are plotted as the mean ± SEM of 3 independent experiments relative to mock treatments; B) The
IC50 values for cisplatin of MIBC cell lines after transfected with miR-34a mimics (mean + SEM; n = 3; *p < 0.05); Mean xenograft tumor volume
C) and weight D) in nude mice groups after indicated treatment (mean ± SEM; n = 3;).
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Figure 4 MiR-34a functioned as a tumor suppressor in MIBC cells. A) The effect of ectopic miR-34a expression on MIBC cell proliferation was
investigated by CCK-8. The miR-34a activity was mediated by transfection with miR-34a mimics or inhibitor respectively. Data are plotted as the
mean ± SEM of 3 independent experiments relative to mock treatments. The effect of ectopic miR-34a expression on MIBC cell tumorgenesis was
investigated by B) colony-formation and C) sphere-formation assay. Quantitative analyses of D) colony and E) sphere numbers (mean + SEM; n = 3;
*p < 0.05). F) Relative miR-34a expression in xenografts; G) Photographs of tumors excised 38 days after inoculation of stably transfected cells into
nude mice; Mean xenograft tumor volume H) and weight I) in nude mice groups after indicated treatment (mean + SEM; n = 3; *p < 0.05).
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we initially measured the expression of some well-
known targets of miR-34a in 5637, T24 and HT-1376
cells following cisplatin treatment, including MYC,
TP53, BCL2, NOTCH1, CDK6, SIRT1, E2F1, CDK4,
HGF, NOTCH2, SOX2 and CD44. However, it seems
that only the expression of CD44 decreased in a doze-
dependent manner following cisplatin treatment, which
correlated with the expression of miR-34a (Figure 5Aand Additional file 1). Moreover, FACS results showed
that the CD44+ bladder cancer stem cells in T24 cells
decreased either transfected with miR-34a or treated
with cisplatin (Figure 5B). Then by luciferase reporter
system and immunobloting, we determined CD44 was
exactly a target of miR-34a in MIBC cells (Figure 5C
and E). Subsequently, we designed another experiment
to further explore this issue. As described, the CD44-
luc-vector we used just contained the seed regions of the
Figure 5 CD44 was a primary target of miR-34a in MIBC cells following cisplatin treatment. A) Relative CD44 expression in MIBC cells after
cisplatin treatment relative to control group (cisplatin 0 μg/ml). B) CD44+ cells proportion decreased following miR-34a overexpression or cisplatin
treatment. C) The seed regions of the miR-34a target sites in CD44 and the luciferase activity assay. D) Cisplatin-induced endogenous miR-34a up-
regulation caused the decrease of CD44-luciferase activity. E) CD44 protein expression was inhibited in miR-34a transfected MIBC cells. Data are
plotted as the mean + SEM of 3 independent experiments. *p < 0.05.
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luciferase activity could only be affected by miR-34a.
Based on this, we measured the luciferase activity in
CD44-luc-transfected 5637 cells after cisplatin treat-
ment. As shown in Figure 5D, luciferase activities de-
creased significantly in the CD44-luc-transfected 5637
cells when treated with cisplatin and such inhibition of
luciferase activities by cisplatin could be abolished when
the potential miR-34a binding sites were mutated. These
results indicated that the downregulation of CD44 ex-
pression following cisplatin treatment was mainly due to
cisplatin-induced endogenous miR-34a upregulation.
Increased CD44 expression can efficiently reverse the
effect of miR-34a on MIBC cell proliferation, colongenic
potential and chemosensitivity
We then tested whether miR-34a inhibited MIBC cell
proliferation, colongenic potential and chemosensitivity
through targeting CD44. Firstly, by using a CD44 siRNA,
we demonstrated that downregulation of CD44 could ef-
ficiently inhibit cell proliferation (Figure 6A), decrease
colony and sphere formation ability (Figure 6B and C) inall three MIBC cell lines, which correlated with the ef-
fect of overexpressed miR-34a. Subsequently, these as-
says were repeated when miR-34a mimics and CD44
expressing vector were co-transfected into 5637 and T24
cells. As shown in Figure 6D-F, CD44 overproduction
appeared to have a dramatic positive effect on tumor cell
growth and tumorigenesis, and importantly, miR-34a in-
duced tumor suppression was largely eliminated upon
the overexpression of CD44. Finally, we measured the
IC50 values of cisplatin for these MIBC cell lines in dif-
ferently treated group (Figure 6G), and the results
showed that overexpression of CD44 could also effi-
ciently reverse the effect of miR-34a on chemosensitivity.
All these data presented here strongly suggesting that
the tumor-suppressive and chemosensitivity effect of
miR-34a was mediated by reducing the production of
CD44 as its predominant target.
Discussion
Bladder cancer is caused by a series of genetic alterations
[15]. Recently, some miRNA expression profiling study
pointed out that the aberrant expression of some
Figure 6 (See legend on next page.)
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Figure 6 The tumor-suppressive and chemosensitivity functions of miR-34a were mediated by reduction the production of CD44.
Downregulation of CD44 by siRNA led to similar effect of miR-34a overexpression on A) cell proliferation (mean ± SEM; n = 3; *p < 0.05) and B-C)
tumorigenity (mean + SEM; n = 3; *p < 0.05). Increased CD44 expression could efficiently reverse the effect of miR-34a on MIBC D) cell proliferation
(mean ± SEM; n = 3; *p < 0.05), E-F) colongenic potential and G) chemosensitivity (mean + SEM; n = 3; *p < 0.05).
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gression [16-19]. miR-34a was one of such miRNAs,
which had been extensively studied in bladder cancer
and many other cancers [8,10,20-24]. However, there
was still a limit in studies focusing on miR-34a in MIBC.
In this study, we determined that miR-34a expression
was frequently decreased in MIBC cell lines and tumor
tissues, which was similar in other cancers. Then, the
possible mechanism that may help to explain the de-
crease of miR-34a in MIBC was investigated. Vogt et, al
indicated that promoter hypermethylation could be an
important reason for the decreased miR-34a expression
in urothelial cancer [24], in our study, using a more
exact method, Massaraay, which could detected up to
500 bp nucleotides containing 14 CpGs, combined with
the data of 5-aza-dC demethylation treatment, we clearly
demonstrated that promoter hypermethylation caused
the decrease of miR-34a expression.
The chemosensitivity of MIBC cells was another area
of our concern. Our present results indicated that there
was a strong association between cisplatin treatment and
miR-34a expression in MIBC. Moreover, we found the
epigenetic alteration of miR-34a promoter following cis-
platin treatment. It had been confirmed that cisplatin
treatment upregulated miR-34a expression regardless of
p53 status [9], while our results also indicated there was
no significant correlation between miR-34a and P53 ex-
pression following cisplatin treatment (Figure 2A and
Additional file 1), so the cisplatin induced epigenetic
alteration could be a reasonable explanation for the up-
regulation of miR-34a expression. Subsequently, in-
creased miR-34a expression induced by cisplatin could
in turn improve cisplatin sensitivity of MIBC cells
in vitro and in vivo. miR-34a has been described a tumor
suppressive miRNA in many kinds of cancers through
inducing tumor cell apoptosis, senescence, cell cycle ar-
rest or repressing metastasis [9,10,14,20-22,25]. Our data
presented here demonstrated that increased miR-34a ex-
pression could efficiently decrease tumorigenity of MIBC
cells. This could partly explain its improved effect on
chemosensitivity.
A miRNA’s function always relies on its targets. To in-
vestigate the primary target of miR-34a that could be the
potential mechanism underlying the association between
the increased miR-34a expression and cisplatin chemo-
sensitivity, we initially measured the expression of some
well-known targets of miR-34a in 5637, T24 and HT-
1376 cells following cisplatin treatment, including MYC,BCL2, NOTCH1, CDK6, SIRT1, E2F1, CDK4, HGF,
NOTCH2, SOX2 and CD44 [7,12,22,23,26,27]. Surpris-
ingly, in spite of a glimpse through qRT-PCR on the
level of mRNA, we still observed a clear inverse correl-
ation between miR-34a and CD44 expression, but not
others. Further experiments validated that the tumor-
suppressive and chemosensitivity effect of miR-34a was
mediated by reducing the production of CD44. As we
know, CD44 have been described as a marker of human
bladder cancer stem cells (CSCs), which have been re-
ported to be resistant to therapeutics [28-30]. Many
studies used chemotherapeutic treatment to enrich can-
cer stem cells. For example, the CD44+CD24lo/2 breast
CSCs are enriched in breast cancer patients who have
received adjuvant chemotherapy [31] and more resistant
to some chemotherapeutic drugs [32]. In mouse models
of mammary tumors, CSCs have also been shown to be
refractory to cisplatin treatment [33]. Furthermore, che-
moresistant colon cancer cells display CSC phenotypes
[34] and CD133+ hepatic CSCs are chemoresistant due
to preferential activation of the Akt pathway [35]. So
here comes confusion. Base on speculations above, after
cisplatin treatment, the bladder CSCs should be
enriched and the CD44 expression and tumorigenity of
the drug resistant cells should be increased, which is op-
posite of our observations. We noticed that similar re-
sults in prostate cancer cells were also reported [36].
These findings suggested that not all chemotherapeutic
treatment is suitable to enrich cancer stem cells.
Conclusion
In this study, we demonstrate that expression of miR-
34a is frequently decreased in bladder cancer tissues and
cell lines through promoter hypermethylation while it is
epigenetically increased in bladder cancer cells following
cisplatin treatment. Increased miR-34a expression sig-
nificantly sensitizes bladder cancer cells to cisplatin
treatment and inhibits the tumorigenicity and prolifera-




In this study, 15 paired MIBC and adjacent normal
tissue specimens were collected from patients who
were diagnosed histopathologically with MIBC and re-
ceived radical cystectomy between September 2010 and
December 2011 in Tongji Hospital, Tongji Medical
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All the samples were immediately snap frozen and stored
in liquid nitrogen. To obtain homogeneous and histo-
logical well-characterized samples for RNA analyses, the
nature of the tissue and its specified composition were
determined by an experienced pathologist. The study was
approved by the Institutional Review Board and Ethics
Committee of Tongji Hospital, Tongji Medical College,
Huazhong University of Science and Technology, and
written informed consent was obtained from all patients.
Cell lines and culture
MIBC cell lines 5637, T24, J82 and HT1376 were pur-
chased from ATCC, 5637 and T24 were maintained in
RPMI-1640 medium; J82 was maintained in DMEM
medium; HT1376 was maintained in MEM medium;
SV-HUC-1 was also purchased from ATCC and main-
tained in DMEM/F-12 medium. Cells were cultured sup-
plemented with 10% fetal bovine serum (FBS) in a
humidified atmosphere of 5% CO2 maintained at 37°C.
Reagents and transfection
Six synthetic, chemically modified short single or double
stranded RNA oligonucleotides (miR-34a mimics,
mimics NC, miR-34a inhibitor, inhibitor NC, agomir-
miR-34a and agomir-NC) were purchased from Ribo
Biotech (Guangzhou, China). Agomir-miRNA is a chem-
ically modified miRNA mimics conjugated with choles-
terol. Prevalidated siRNA specific for CD44 and a
nonsilencing siRNA control were purchased from Gene-
pharma Biotech (Shanghai, China). Lenti-miR-34a and
Lenti-NC were purchased from Genechem Biotech
(Shanghai, China) Primary antibody CD44 (1:1000) and
GAPDH (1:10000) were purchased from Sigma-Aldrich,
St. Louis, MO. Oligonucleotide and plasmid transfection
was done by using X-tremeGENE siRNA Transfection
Reagent (Roche) and FuGene HD Transfection Reagent
(Roche) respectively, according to the manufacture’s
protocol. The lentivirus infection was carried out accord-
ing to the manufacture’s protocol and he MOI for 5637,
T24 and HT1376 cells was 10, 10 and 5 respectively.
DNA extraction and methylation analysis
Genomic DNA was isolated using QIAamp DNA Mini Kit
(Qiagen, Valencia, CA) and bisulfite modification of the
genomic DNA was carried out using an Epitect Bisulfite
Kit (Qiagen, Valencia, CA) according to the manufac-
turer’s instructions. Quantitative methylation analysis of
the promoter of miR-34a was performed using the Seque-
nom MassARRAY platform (CapitalBio, Beijing, China) as
previous study description [37]. The sequence and primer
sets used were shown in Additional file 2. The spectra
methylation ratios were generated by Epityper software
version 1.0 (Sequenom, San Diego, CA).Animal experiment
Tumorigenicity in nude mice was determined as de-
scribed previously [23,38]. To evaluate the chemosensi-
tivity effect of miR-34a, four groups of 6 mice each were
injected subcutaneously with T24 cells at a single site. 17
days after injection when appreciable tumor formed
subcutaneously, agomir-miR-34a or agomir-NC were
injected combined with cisplatin or PBS in tumor. To
evaluate the tumorigenity of miR-34a, two groups of 8
mice each were injected subcutaneously with miR-34a/
NC stably expressing T24 cells constructed by lentivector
infection and puromycin screening. Tumor onset mea-
sured with calipers at the site of injection every three day
by two trained laboratory staffs at different times on the
same day 14 weeks after injection when appreciable
tumor formed subcutaneously. Tumor volume was calcu-
lated using the formula, V = 0.5ab2, where a represent the
larger and b represents the smaller of the 2 perpendicular
indexes. Animals were sacrificed 33 days or 38 days after
injection and these tumors were weighed. Nude mice were
manipulated and cared for in the Experiment Animal
Center of the Tongji Medical College and was approved by
the Ethics Committee of Tongji Medical College, Huazhong
University of Science and Technology (Wuhan, Hubei,
Province, P.R. China).
Statistical analysis
At least three independent experiments were completed
for each analysis described in this article. Data are
shown as mean ± standard deviation (SD). Paired ana-
lysis was performed by Student’s t-test, and multiple
group comparison was performed by one-way analysis of
variance (ANOVA) using SPSS 19.0 software. P < 0.05
was considered statistically significant.
Additional methods are listed in Additional file 3:
Supplementary Materials and Methods.
Additional files
Additional file 1: Expression of some well-known targets of miR-34a
in 5637, T24 and HT-1376 cells following cisplatin treatment. mRNA
expression of indicated genes were detected by qPCR.
Additional file 2: CpG sites in the promoter region of miR-34a
(n=14), and sequences of the primers used for amplification of
converted DNA for sequenom massarray analysis.
Additional file 3: Supplementary materials and methods.
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